Paul joined Venture Investors in 2006 as a Managing Director. Paul is focused on the firm’s therapeutics practice. Paul worked as a part-time Analyst for Venture Investors from 1989 to 1992 while receiving his MBA and joined the firm’s Investment Advisory Committee in 2001.
Paul serves on the Board of Directors of FluGen, Invenra, and Madison Vaccines. He is a former board member of Aerpio Pharmaceuticals (NASDAQ:ARPO), Akebia Therapeutics (NASDAQ:AKBA), Neurovance (acquired by Otsuka for up to $1 billion), and Tissue Regeneration Systems (Observer).
Paul has over 20 years of operating experience in the biotech and pharmaceutical industries. Previously, he served as President of Venture Investors portfolio company, Gala Design, Inc., and of the Gala Biotech business unit of Cardinal Health after its acquisition. Previously, Paul served as Vice President of Business Development of 3-Dimensional Pharmaceuticals, a venture capital backed company with a drug discovery platform that successfully completed an IPO during his tenure, and was subsequently acquired by Johnson & Johnson. Prior to that, Paul worked as Director of Licensing for Wyeth-Ayerst, which was a division of American Home Products (now part of Pfizer). Earlier, he served as Director of Business Development and Research for the Scientific Protein Labs (SPL) division of American Home Products. He began his career in industry as the Director of Operations of Columbia Research Labs.
In his spare time, Paul enjoys spending time with family (biking, swimming, and generally goofing off), learning more about wine (and hopefully not buying more!), cooking, and still playing softball and golf as time permits.